Description

Description

Inosita Plus 50/500mg is a prescription combination tablet manufactured by PharmEvo, bringing together two well-established oral anti-diabetic medicines, Sitagliptin and Metformin, in a single dose. Sitagliptin belongs to the DPP-4 inhibitor class and works by supporting the body’s natural incretin hormones, while Metformin belongs to the biguanide class and works mainly by reducing the amount of glucose the liver produces while improving the body’s sensitivity to insulin. Combining the two allows for a dual-action approach to blood sugar control in a single tablet, which can simplify treatment for adults managing type 2 diabetes mellitus. Each pack contains 28 tablets, giving patients a convenient supply for ongoing, doctor-supervised diabetes care.

Ingredients

Each film-coated tablet of Inosita Plus 50/500mg contains two active pharmaceutical ingredients: 50 milligrams of Sitagliptin, present as its phosphate monohydrate form, and 500 milligrams of Metformin hydrochloride. The tablet’s film coating helps make it easier to swallow and offers some protection to the active ingredients as they pass through the stomach before absorption. Beyond the two active substances, the tablet also contains standard inactive ingredients such as binders and coating agents, included only to support the tablet’s shape, texture, and shelf stability.

Dosage Form

Inosita Plus 50/500mg is supplied as an oral, film-coated combination tablet. As a solid dosage form, it is meant to be swallowed whole with water and should not be crushed, chewed, or split, since doing so could disrupt how the two active ingredients are released and absorbed in the body.

Uses

Inosita Plus 50/500mg is used to help manage blood glucose levels in adults with type 2 diabetes mellitus, particularly in cases where a single anti-diabetic medicine alone has not achieved adequate blood sugar control. Sitagliptin helps raise natural incretin hormone levels that prompt insulin release in response to elevated blood sugar and reduce glucagon secretion, while Metformin works to lower the liver’s glucose output and improve how effectively the body’s cells respond to insulin. Together, this combination is intended to provide more comprehensive glycemic control than either medicine might achieve on its own, and it is typically used alongside a controlled diet and regular physical activity as part of an overall diabetes management plan.

How to Use

Inosita Plus 50/500mg is generally taken with meals, as directed by the prescribing doctor, since taking it with food can help reduce the stomach-related side effects sometimes associated with Metformin. The exact frequency and timing of doses should follow the doctor’s specific instructions, as this can vary based on the patient’s overall treatment plan. The tablet should be swallowed whole with a glass of water rather than chewed or crushed. Patients should not change their dose or stop the medicine without medical guidance, and regular blood sugar monitoring along with periodic kidney and liver function checks is generally recommended while on this combination therapy.

Side Effects

The most commonly reported side effects of Inosita Plus are related to the digestive system, including nausea, mild stomach discomfort, diarrhea, or a reduced appetite, particularly when treatment is first started. Some patients may also experience headache or mild dizziness. Because the tablet contains Metformin, there is a rare but serious risk of a condition called lactic acidosis, especially in people with kidney problems, liver impairment, dehydration, or excessive alcohol use; warning signs can include unusual tiredness, muscle pain, difficulty breathing, or stomach discomfort, and this requires urgent medical attention. As with Sitagliptin-containing medicines, there is also a small chance of low blood sugar when this combination is used alongside other diabetes treatments, along with rare reports of pancreatitis or allergic reactions.

Pregnancy & Breastfeeding

There is limited established safety information on the use of this Sitagliptin and Metformin combination during pregnancy or while breastfeeding. For this reason, Inosita Plus should only be used in these circumstances if a doctor decides the potential benefit outweighs any possible risk to the mother or baby. Women who are pregnant, planning to conceive, or currently breastfeeding should discuss suitable diabetes management options with their healthcare provider before starting or continuing this medication.

Storage Instructions

Inosita Plus tablets should be stored at room temperature, generally below 30°C, in a dry place away from direct sunlight, excess heat, and moisture. Keeping the tablets in their original blister packaging until they are needed helps protect them from humidity. The medicine should always be kept out of the reach of children and pets, and any expired or unused tablets should be disposed of properly rather than stored indefinitely.

FAQs

Why is Inosita Plus prescribed instead of Sitagliptin or Metformin alone?
It is generally prescribed when a single medicine has not brought blood sugar under adequate control, allowing both mechanisms of action to work together in one tablet.

Should Inosita Plus be taken with food?
Yes, it is usually recommended to take it with meals to help reduce the risk of stomach upset associated with the Metformin component.

Is Inosita Plus suitable for people with kidney problems?
This depends on the severity of kidney impairment, since the Metformin component carries a risk of lactic acidosis in patients with significant renal issues; a doctor must assess kidney function before and during treatment.

Can this medicine be used for type 1 diabetes?
No, Inosita Plus is intended specifically for type 2 diabetes mellitus and is not suitable for type 1 diabetes or diabetic ketoacidosis.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.